Do you want to read an article? Please log in or register.
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Heart Failure
Related content
Heart Failure
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Eur Heart J
Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1093/eurheartj/ehaa1007
Heart Failure
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
N Engl J Med.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators
doi: 10.1056/NEJMoa2022190.
Atrial FibrillationHeart Failure
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
Eur J Heart Fail.
Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, Inzucchi SE, Fitchett D, Anker SD, Marx N, Wanner C, Zinman B, Verma S
doi: 10.1002/ejhf.1663.
COMMENTED
Heart Failure
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M
doi: 10.1016/S0140-6736(20)31824-9
RECOMMENDED
Heart, Artery and Coronary DiseasesHeart Failure
Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation
Packer M, Anker SD, Butler J, Filippatos GS, Ferreira JP, Pocock S, Carson PE, Anand IS, Doehner W, Haass M, Komajda M, Miller AB, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1161/CIRCULATIONAHA.120.051783
Heart Failure
Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial
Circulation
Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod M
doi: 10.1161/CIRCULATIONAHA.120.052503
Heart Failure
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Eur Heart J
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Rocca HB, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F
doi: 10.1093/eurheartj/ehaa968
Heart Failure
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial
J Am Coll Cardiol
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators.
doi: 10.1016/j.jacc.2021.01.033
Cardiovascular Risk and Diseases
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
JAMA Cardiol
Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD
doi: 10.1001/jamacardio.2021.0660